CA2572498A1 - Biphasic capsule formulation - Google Patents

Biphasic capsule formulation Download PDF

Info

Publication number
CA2572498A1
CA2572498A1 CA002572498A CA2572498A CA2572498A1 CA 2572498 A1 CA2572498 A1 CA 2572498A1 CA 002572498 A CA002572498 A CA 002572498A CA 2572498 A CA2572498 A CA 2572498A CA 2572498 A1 CA2572498 A1 CA 2572498A1
Authority
CA
Canada
Prior art keywords
pharmaceutical formulation
release phase
formulation according
glyceride
biphasic pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002572498A
Other languages
French (fr)
Other versions
CA2572498C (en
Inventor
Stephen George Barnwell
Simon Higginbottom
Ian Peter Whelan
Stephen John Burns
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PII Drug Delivery LLC
Original Assignee
Pii Drug Delivery, Llc
Stephen George Barnwell
Simon Higginbottom
Ian Peter Whelan
Stephen John Burns
Cortecs Limited
Provalis Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939325445A external-priority patent/GB9325445D0/en
Application filed by Pii Drug Delivery, Llc, Stephen George Barnwell, Simon Higginbottom, Ian Peter Whelan, Stephen John Burns, Cortecs Limited, Provalis Uk Limited filed Critical Pii Drug Delivery, Llc
Priority claimed from CA002179041A external-priority patent/CA2179041C/en
Publication of CA2572498A1 publication Critical patent/CA2572498A1/en
Application granted granted Critical
Publication of CA2572498C publication Critical patent/CA2572498C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Abstract

Capsule formulations are provided containing at least two different fill compositions which are prevented from mixing either by providing both of the fill compositions as solids or by providing a physical barrier which separates the fill compositions so that they are prevented from mixing. The invention has the advantage that two different formulations can be provided in a single capsule without one of the formulations having an adverse effect on the other.

Claims (6)

1. A biphasic pharmaceutical formulation comprising a solid rapid release phase and a solid sustained release phase, wherein said rapid release phase remains solid at a temperature below 30°C.
2. The biphasic pharmaceutical formulation according to claim 16, wherein the rapid release phase comprises a pharmaceutically active substance and a glyceride having a melting point above 30°C.
3. The biphasic pharmaceutical formulation according to claim 17, wherein the glyceride is a saturated polyglycolyzed glyceride.
4. The biphasic pharmaceutical formulation according to claim 17, wherein the glyceride is a hydrogenated fatty acid ester.
5. The biphasic pharmaceutical formulation according to claim 17, wherein the rapid release phase and the sustained release phase comprise a C12-C24 fatty acid.
6. The biphasic pharmaceutical formulation according to claim 20, wherein the C12-C24 fatty acid is oleic acid.
CA2572498A 1993-12-13 1994-12-12 Biphasic capsule formulation Expired - Fee Related CA2572498C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9325445.6 1993-12-13
GB939325445A GB9325445D0 (en) 1993-12-13 1993-12-13 Pharmaceutical formulations
CA002179041A CA2179041C (en) 1993-12-13 1994-12-12 Biphasic capsule formulation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002179041A Division CA2179041C (en) 1993-12-13 1994-12-12 Biphasic capsule formulation

Publications (2)

Publication Number Publication Date
CA2572498A1 true CA2572498A1 (en) 1995-06-22
CA2572498C CA2572498C (en) 2010-07-13

Family

ID=37806595

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2572498A Expired - Fee Related CA2572498C (en) 1993-12-13 1994-12-12 Biphasic capsule formulation

Country Status (1)

Country Link
CA (1) CA2572498C (en)

Also Published As

Publication number Publication date
CA2572498C (en) 2010-07-13

Similar Documents

Publication Publication Date Title
EE03425B1 (en) Ciclosporin Preparations for Oral Administration with Simple Composition and High Bioavailability and Method of Preparation
CA2366754A1 (en) Oral pharmaceutical compositions containing long-chain triglycerides and lipophilic surfactants
CA2185347A1 (en) A carrier for hydrophobic drugs and a pharmaceutical composition based thereon
HK1033263A1 (en) Pharmaceutical compositions capable of being gelled
CA2383036A1 (en) Solid lipid formulations
CA2376202A1 (en) Novel preparation and administration form comprising an acid-labile active compound
CA2466868A1 (en) Oral capsule formulation with increased physical stability
ATE152613T1 (en) COMPOSITION WHICH FORMES A MICROEMULSION UPON PERORAL ADMINISTRATION
CA2137764A1 (en) Pharmaceutical compositions comprising solutions or dispersions of a staurosporine active ingredient in a saturated polyalkylene glycol glyceride
WO1999008666A3 (en) Pharmaceutical composition comprising an azateroid
CA2572498A1 (en) Biphasic capsule formulation
WO2001047497A3 (en) Controlled release pharmaceutical composition containing tramadol hydrochloride
CA2203566A1 (en) Percutaneously administration preparation
CA2197413C (en) A pharmaceutical or veterinary composition
MY130474A (en) Oral pharmaceutical compositions containing long-chain triglycerides and lipophilic surfactants

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed